Reuters logo
a month ago
BRIEF-U.S. FDA approves Puma's Nerlynx for extended adjuvant treatment of HER2-positive early stage breast cancer
July 17, 2017 / 9:41 PM / a month ago

BRIEF-U.S. FDA approves Puma's Nerlynx for extended adjuvant treatment of HER2-positive early stage breast cancer

July 17 (Reuters) - Puma Biotechnology Inc

* U.S. Food and Drug Administration approves Puma's Nerlynx (neratinib) for extended adjuvant treatment of HER2-positive early stage breast cancer

* Puma Biotechnology Inc - expects Neratinib to become commercially available in September 2017 and to be marketed as Nerlynx Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below